Research advances in transarterial chemoembolization combined with sorafenib in treatment of advanced hepatocellular carcinoma

At present, transarterial chemoembolization (TACE) combined with sorafenib is commonly used for patients with advanced hepatocellular carcinoma (HCC) who have lost the opportunity for surgery, and yet no consensus has been reached on the specific therapeutic paradigm. This article reviews the treatment modes of TACE combined with sorafenib and their effect and safety in the treatment of HCC. It is pointed out that these treatment modes have their own advantages and disadvantages and await further clinical studies, in order to provide a reference for the treatment of patients with advanced HCC